Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | RGS12 | O14924 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024163 | 0.82 | SYK (0.42) | ALDH1A1MAPK1KMT2ARAB9ASLC2A1 | |
| SCHEMBL3316553 | 0.78 | CCNA2 (0.50) | ALDH1A1HPGDMAPTCCNA2CDK2 | |
| SCHEMBL9004786 | 0.74 | MAPT (0.50) | ALDH1A1MAPK1HPGDMEN1KMT2A | |
| SCHEMBL28916259 | 0.70 | ALDH1A1 (0.52) | ALDH1A1MAPK1HPGDMEN1KMT2A | |
| SCHEMBL12124929 | 0.69 | RAB9A (0.69) | ALDH1A1HPGDMEN1KMT2ARAB9A | |
| SCHEMBL12253193 | 0.69 | MEN1 (0.83) | ALDH1A1HPGDMEN1KMT2ARAB9A | |
| SCHEMBL1782591 | 0.68 | PTK2 (0.49) | MAPK1HPGDMEN1KMT2AMAPT | |
| SCHEMBL3019337 | 0.68 | PTK2 (0.46) | MAPK1MAPTNFKB1LMNASYK | |
| SCHEMBL3899986 | 0.67 | NAMPT (0.64) | ALDH1A1HPGDMEN1KMT2ARAB9A | |
| SCHEMBL9644563 | 0.66 | RAB9A (0.63) | ALDH1A1HPGDMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125819-B1 | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases | BRISTOL MYERS SQUIBB CO (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| EP-2125819-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116064-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | ALDH1A1 4220/4885MAPK1 205/4885HPGD 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.